BillionToOne, Inc. (BLLN)
NASDAQ: BLLN · Real-Time Price · USD
99.94
-9.12 (-8.36%)
At close: Oct 6, 2026, 4:00 PM EDT
99.50
-0.44 (-0.44%)
After-hours: Oct 6, 2026, 4:31 PM EDT
BillionToOne Revenue
BillionToOne had revenue of $109.45M in the quarter ending June 30, 2026, with 64.40% growth. This brings the company's revenue in the last twelve months to $397.41M, up 90.12% year-over-year. In the year 2025, BillionToOne had annual revenue of $305.11M with 99.97% growth.
Revenue (ttm)
$397.41M
Revenue Growth
+90.12%
P/S Ratio
11.92
Revenue / Employee
$557,380
Employees
713
Market Cap
4.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 305.11M | 152.53M | 99.97% |
| Dec 31, 2024 | 152.58M | 80.85M | 112.72% |
| Dec 31, 2023 | 71.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
BLLN News
- 5 days ago - BillionToOne price target raised to $128 from $125 at Guggenheim - TheFly
- 27 days ago - BillionToOne Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference - PRNewsWire
- 4 weeks ago - BillionToOne initiated with a Buy at Canaccord - TheFly
- 5 weeks ago - BillionToOne announces the launch of Northstar Origin - TheFly
- 5 weeks ago - BillionToOne launches Northstar Origin, a new liquid biopsy test - TheFly
- 5 weeks ago - BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin - PRNewsWire
- 7 weeks ago - BillionToOne announces publication of study on cfDNA fetal risk assessment - TheFly